Interestingly, in a clinical trial, basimglurant, a selective negative mGluR5 allosteric modulator improved Montgomery-Asberg Depression Rating Scale, and Depressive Symptomatology–Self-Report of MDD patients at the secondary endpoint of the trial [178]. This evidence concerns the gene GRM5 and major depressive disorder.